• Follow us:


VIDEO: 02/26/2021

Rock Stars of R&D, Episode 29, Ross Youngs

An Engineering Entrepreneur in Technology and now as CEO of Biosortia, Microbiomes and Microbiomics, Ross spent a career driving breakthrough technologies to fruition and acceptance.

VIDEO: 02/10/2021

Ross Youngs’ presentation during the “Innovation Spotlight”

Segment of the meeting of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB)

VIDEO: 09/25/2020

Jesse McLaughlin & Ross Youngs.

In the world of drug discovery, for the most part, it hasn’t changed much in decades. Ross Youngs, CEO of Biosortia Pharmaceuticals is looking to change that with a better understanding of the microbiome.

PODCAST: 09/24/2020

Through an interesting turn of events, Biosortia discovered they had access to large amounts of Aquatic Microbiome. With a broad range of capabilities, they are able to extrapolate this into drug discovery. Ross believes that Biosortia’s ability to mine microbiome on such a large scale will change drug discovery in the coming years.

PODCAST: 08/05/2020

Delighted to share Episode 1, Season 1 of The Sophia Consulting Firm’s “Amplifying Scientific Innovation #Podcast” with Ross Youngs, Founder, and CEO, Biosortia Pharmaceuticals.

PODCAST: 04/02/2020

Ross Youngs has spent over 30 years inventing products, technologies, and processes for a variety of industries, and holds over 75 patents worldwide. He is driven to innovate by a focus on what is better, faster, and less expensive. Ross’ recent major innovations include an R&D 100 Award for collaboration on biopolymer technologies. In 2009, Biosortia was awarded a $6 million ARPA-E (U.S. Dept. of Energy R&D) grant for its algal harvesting technology, which helped lead to the development of Biosortia’s drug discovery platform.

VIDEO: 09/16/2019

Biosortia Pharmaceutical Presentation.

Enabling new, faster and less expensive drug discovery through unprecedented access to microbiome chemistry.

VIDEO: 07/12/2019

The Donna Drake Show Live It Up with Ross O Youngs on Biosortia Pharmaceutical.

Extract Value from Natural and Chemically Modified Compounds.

Pre-clinical portfolio of microbiome-derived immune-modulating peptides and other small molecules with exclusive technologies and the scientific expertise for discovering, expanding, and advancing a valuable IO/I pipeline.

Pin It on Pinterest